Schrödinger Halts CDC7 Inhibitor After Two Patient Deaths
Key Points: 1. Schrödinger discontinued its SGR-2921 CDC7 inhibitor program following two treatment-related deaths in a Phase 1 trial. 2. ...
Tag: AML
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2 Minute Medicine: Pharma Roundup – Landmark lung approval, billion-dollar obesity drug deal, oncology safety halt, and GSK’s China push [August 14 2025]
FDA Approves First-Ever Treatment for Non-Cystic Fibrosis Bronchiectasis Late last week, the U.S. Food and Drug Administration approved Insmed’s Brinsupri ...
Mitoxantrone is superior to liposomal daunorubicin in MRD (measurable residual disease)-guided treatment of AML in pediatric cases
1. Mitoxantrone enhances five-year event-free survival over liposomal daunorubicin in MRD-guided pediatric AML treatment. 2.High-risk patients identified by MRD guidance ...
Quizartinib improves overall median survival in patients with acute myeloid leukemia
1. Overall survival in the quizartinib group was 31.9 months compared to 15.1 months in the placebo group. 2. Proportion ...
#VisualAbstract: Oral azacytidine improves survival outcomes as maintenance therapy for patients with acute myeloid leukemia
1. Oral azacytidine also known as CC-486 has been found to improve survival outcomes in patients with acute myeloid leukemia. ...
Improved survival with bufulfan-cyclophosphamide combination vs total body irradiation
Image: PD 1. IV busulfan combined with cyclophosphamide (BuCy) is associated with better leukemia-free and overall survival in acute myeloid ...
Rituximab linked with reduced chronic immune disease following stem cell transplantation
Image: PD AML 1. Rituximab use is linked with a reduction in chronic graft-vs-host disease following peripheral blood stem cell ...
